Tags

Type your tag names separated by a space and hit enter

Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease.
Am J Cardiol 2008; 101(10A):58D-68DAJ

Abstract

Oxidative stress and inflammation are implicated in several different manifestations of cardiovascular disease (CVD). They are generated, in part, from the overproduction of reactive oxygen species (ROS) and reactive nitrogen species (RNS) that activate transcriptional messengers, such as nuclear factor-kappaB, tangibly contributing to endothelial dysfunction, the initiation and progression of atherosclerosis, irreversible damage after ischemic reperfusion, and even arrhythmia, such as atrial fibrillation. Despite this connection between oxidative stress and CVD, there are currently no recognized therapeutic interventions to address this important unmet need. Antioxidants that provide a broad, "upstream" approach via ROS/RNS quenching or free radical chain breaking seem an appropriate therapeutic option based on epidemiologic, dietary, and in vivo animal model data. However, human clinical trials with several different well-known agents, such as vitamin E and beta-carotene, have been disappointing. Does this mean antioxidants as a class are ineffective, or rather that the "right" compound(s) have yet to be found, their mechanisms of action understood, and their appropriate targeting and dosages determined? A large class of potent naturally-occurring antioxidants exploited by nature-the oxygenated carotenoids (xanthophylls)-have demonstrated utility in their natural form but have eluded development as successful targeted therapeutic agents up to the present time. This article characterizes the mechanism by which this novel group of antioxidants function and reviews their preclinical development. Results from multiple species support the antioxidant/anti-inflammatory properties of the prototype compound, astaxanthin, establishing it as an appropriate candidate for development as a therapeutic agent for cardiovascular oxidative stress and inflammation.

Authors+Show Affiliations

John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA. fpashkow@cardaxpharma.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18474276

Citation

Pashkow, Fredric J., et al. "Astaxanthin: a Novel Potential Treatment for Oxidative Stress and Inflammation in Cardiovascular Disease." The American Journal of Cardiology, vol. 101, no. 10A, 2008, 58D-68D.
Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol. 2008;101(10A):58D-68D.
Pashkow, F. J., Watumull, D. G., & Campbell, C. L. (2008). Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. The American Journal of Cardiology, 101(10A), 58D-68D. doi:10.1016/j.amjcard.2008.02.010.
Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: a Novel Potential Treatment for Oxidative Stress and Inflammation in Cardiovascular Disease. Am J Cardiol. 2008 May 22;101(10A):58D-68D. PubMed PMID: 18474276.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. AU - Pashkow,Fredric J, AU - Watumull,David G, AU - Campbell,Charles L, PY - 2008/6/24/pubmed PY - 2008/7/3/medline PY - 2008/6/24/entrez SP - 58D EP - 68D JF - The American journal of cardiology JO - Am. J. Cardiol. VL - 101 IS - 10A N2 - Oxidative stress and inflammation are implicated in several different manifestations of cardiovascular disease (CVD). They are generated, in part, from the overproduction of reactive oxygen species (ROS) and reactive nitrogen species (RNS) that activate transcriptional messengers, such as nuclear factor-kappaB, tangibly contributing to endothelial dysfunction, the initiation and progression of atherosclerosis, irreversible damage after ischemic reperfusion, and even arrhythmia, such as atrial fibrillation. Despite this connection between oxidative stress and CVD, there are currently no recognized therapeutic interventions to address this important unmet need. Antioxidants that provide a broad, "upstream" approach via ROS/RNS quenching or free radical chain breaking seem an appropriate therapeutic option based on epidemiologic, dietary, and in vivo animal model data. However, human clinical trials with several different well-known agents, such as vitamin E and beta-carotene, have been disappointing. Does this mean antioxidants as a class are ineffective, or rather that the "right" compound(s) have yet to be found, their mechanisms of action understood, and their appropriate targeting and dosages determined? A large class of potent naturally-occurring antioxidants exploited by nature-the oxygenated carotenoids (xanthophylls)-have demonstrated utility in their natural form but have eluded development as successful targeted therapeutic agents up to the present time. This article characterizes the mechanism by which this novel group of antioxidants function and reviews their preclinical development. Results from multiple species support the antioxidant/anti-inflammatory properties of the prototype compound, astaxanthin, establishing it as an appropriate candidate for development as a therapeutic agent for cardiovascular oxidative stress and inflammation. SN - 0002-9149 UR - https://www.unboundmedicine.com/medline/citation/18474276/Astaxanthin:_a_novel_potential_treatment_for_oxidative_stress_and_inflammation_in_cardiovascular_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(08)00219-1 DB - PRIME DP - Unbound Medicine ER -